- Home
- GMM vs IGMS Comparison
GMM vs IGMS Comparison
Compare GMM & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- IGMS
- Stock Information
- Founded
- GMM 2017
- IGMS 1993
- Country
- GMM China
- IGMS United States
- Employees
- GMM N/A
- IGMS N/A
- Industry
- GMM
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- IGMS Health Care
- Exchange
- GMM Nasdaq
- IGMS Nasdaq
- Market Cap
- GMM 70.8M
- IGMS 82.1M
- IPO Year
- GMM 2023
- IGMS 2019
- Fundamental
- Price
- GMM $3.17
- IGMS $1.16
- Analyst Decision
- GMM
- IGMS Hold
- Analyst Count
- GMM 0
- IGMS 8
- Target Price
- GMM N/A
- IGMS $6.14
- AVG Volume (30 Days)
- GMM 33.3K
- IGMS 182.2K
- Earning Date
- GMM 05-16-2025
- IGMS 05-07-2025
- Dividend Yield
- GMM N/A
- IGMS N/A
- EPS Growth
- GMM 62.17
- IGMS N/A
- EPS
- GMM 6.37
- IGMS N/A
- Revenue
- GMM $41,360,953.00
- IGMS $2,679,000.00
- Revenue This Year
- GMM N/A
- IGMS $106.64
- Revenue Next Year
- GMM N/A
- IGMS $68.35
- P/E Ratio
- GMM $0.54
- IGMS N/A
- Revenue Growth
- GMM 53.82
- IGMS 25.77
- 52 Week Low
- GMM $0.21
- IGMS $1.11
- 52 Week High
- GMM $4.97
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- GMM 35.19
- IGMS 36.58
- Support Level
- GMM $3.02
- IGMS $1.11
- Resistance Level
- GMM $3.49
- IGMS $1.31
- Average True Range (ATR)
- GMM 0.43
- IGMS 0.08
- MACD
- GMM -0.09
- IGMS 0.03
- Stochastic Oscillator
- GMM 9.71
- IGMS 25.64
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.